Talphera (NASDAQ:TLPH) Coverage Initiated at Rodman & Renshaw

Investment analysts at Rodman & Renshaw initiated coverage on shares of Talphera (NASDAQ:TLPH) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Rodman & Renshaw’s price target would suggest a potential upside of 470.61% from the company’s previous close.

TLPH has been the subject of a number of other reports. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Talphera in a report on Tuesday, January 21st.

Talphera Stock Performance

Shares of NASDAQ:TLPH opened at $0.70 on Tuesday. Talphera has a 52-week low of $0.50 and a 52-week high of $1.61. The business’s 50 day simple moving average is $0.65 and its two-hundred day simple moving average is $0.81. The firm has a market cap of $11.94 million, a P/E ratio of -1.02 and a beta of 0.28.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC purchased a new position in shares of Talphera, Inc. (NASDAQ:TLPH) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera as of its most recent SEC filing. 37.67% of the stock is currently owned by institutional investors and hedge funds.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.